Dr Reddy’s Laboratories Ltd and PanTheryx, Inc., have entered into a licensing agreement that grants the exclusive right to market and distribute PanTheryx’s nutritional intervention, DiaResQ, for infectious diarrhoea in India and Nepal.
Dr Reddy’s will market the product in India and Nepal under the Reliqua brand.
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognised in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
GV Prasad, CEO of Dr. Reddy’s, in a statement said, “This innovative product will address a significant unmet need in the area of diarrhoea. By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr. Reddy’s can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”